A stressful life or death: Combinatorial proteotoxic approaches to cancerselective therapeutic vulnerability

Paul Workman; Faith E. Davies

doi:10.18632/oncotarget.266

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Rapamycin Press LLC dba Impact Journals is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack... This malicious action will be reported to the FBI.

Commentaries:

A stressful life or death: Combinatorial proteotoxic approaches to cancerselective therapeutic vulnerability

PDF | Full Text | How to cite

Oncotarget. 2011; 2:277-280. https://doi.org/10.18632/oncotarget.266

Paul Workman¹ and Faith E. Davies²

¹Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG UK

²Myeloma Targeted Treatment Team, Divisions of Molecular Pathology, Clinical Studies & Cancer Therapeutics, Institute of Cancer Research, Brookes Lawley Building, 15 Cotswold Road, Sutton, Surrey SM2 5NG UK

Commentary on: Neznanov, N., Komarov, A., Neznanova, L., Stanhope-Baker, P., & Gudkov, A. (2011). Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget, 2(3), 209-221.

Received: April 21, 2011; Accepted: April 21, 2011; Published: April 21, 2011;

Correspondence:

Paul Workman, e-mail:

Faith E Davies, e-mail:

Publication Alerts

Oncoscience

Post-Publication Promotion

Commentaries:

A stressful life or death: Combinatorial proteotoxic approaches to cancerselective therapeutic vulnerability